I'm prepared to admit I got this one badly wrong. In a year where small biotechs with seemingly far less substance have shined, BIT has been profoundly disappointing. There have been spectacular gains across the small biotech space, but BIT has languished badly, plumbing new lows on a daily basis. I attribute this to management's inability to do deals, or even just to promote the company effectively.
Utterly disappointing.
Without a hope, page-214
-
- There are more pages in this discussion • 340 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
